GENE ONLINE|News &
Opinion
Blog

2021-04-29| FundingR&D

Arch Oncology Secures $105 Million in Funding for Advancing Anti-CD47 Therapy

by Ruchi Jhonsa
Share To

Arch Oncology, a clinical-stage biotechnology company working on cancer therapy targeting the CD47’s “don’t eat me” signal, announced on April 27th the closure of a $105 million Series C financing.

The financing round was led by several investors, including some old investors such as Roche Venture Fund, RiverVest Venture Partners, and Lightchain and some new additions, including Adage Capital Management, Point72 Asset Management, Avego Healthcare Capital, FMB Research, and Broadfin Holdings. The funding will be used to push the company’s anti-CD47 antibody, AO-176, through the clinic and into new trials.

Why Target CD47?

CD47 is a cell surface receptor expressed at high levels in multiple cancers. Cancer cells use the protein as a shield to protect it from being eaten up by immune cells such as macrophages. The protein helps cancer cells escape immune attacks by forming a complex with signal regulatory protein alpha.

Arch’s anti-CD47 antibody works by blocking this interaction and prevents cancer cells from escaping macrophage-mediated phagocytosis. It also has certain unique properties, which distinguishes it from anti-CD47 treatments developed by other companies. This includes “lower binding to normal cells and negligible binding to red blood cells, enhanced binding to CD47 in acidic environments found in tumors and induction of programmed and immunogenic cell death.”

The treatment is currently in the Phase1/2 clinical trials for select solid tumors and hematologic malignancies. It is being tested alone or in combination with the chemotherapy drug paclitaxel. In the future, Arch also plans to expand the drug’s scope by combining it with Merck’s Keytruda and other standard therapies used for multiple myeloma.

Overcrowded anti-CD47 Market

In the past few years, several companies have jumped into the search for a cancer therapy that blocks CD47. The surge has been attributed to the remarkable therapeutic promise of therapies targeting the CD47/SIRPalpha axis.

Last year, I-Mab Biopharma, a Chinese clinical-stage biopharmaceutical company, announced the dosing of the first patient with their anti-CD47 monoclonal antibody in the Phase 1/2a trial. Later that year, AbbVie made a licensing agreement with I-Mab for its anti-CD47 therapy.

Gilead Sciences entered the CD47 space after inking a $4.9 billion deal with Forty Seven in 2020. In March this year, Sorrento received FDA clearance for testing its anti-CD47 monoclonal antibody in the Phase 1B trial in patients with relapsed or refractory malignancies.

Related Article: Illumina Enters Yet Another Oncology Partnership to Capitalize on its Pan-Cancer Assay

 

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
The Latest Talk in Cancer Immunotherapy: A Brief Overview of Developments & Current Players in the Exosome Space
2025-04-23
From Cancer to Cosmetics, Physiological to Pathological – The Field of Exosomes Full of Endless Opportunities
2025-04-22
NGS
New Philippines NGS Center Targets Critical Gaps in Genomic Care
2025-03-31
LATEST
World Vaccine Congress Washington 2025 Recap: Urgent Calls for Trust, Tech, and Global Access
2025-04-25
Astellas’ Transformation Journey: From Merger to Global Player, Betting on the Edge of Innovation and Risk?
2025-04-25
Roche Announces Massive 50 Billion Dollar Investment in the United States
2025-04-25
Steminent Stands Ready to Showcase Novel MSC-based Therapy for Spinocerebellar Ataxia at Global Stage
2025-04-24
Arkansas Medicaid Work Requirements Led to Coverage Loss for a Significant Number of Recipients
2025-04-24
Boehringer agrees new partnership to advance first-in-class precision cancer therapies
2025-04-24
Bristol Myers Squibb Schizophrenia Drug Fails Pivotal Test as an Add-On to Antipsychotics
2025-04-24
EVENT
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
2025-05-03
29th Taiwan Joint Cancer Conference 2025
Taipei, Taiwan
2025-05-05
Swiss Biotech Day 2025
Basel, Switzerland
2025-05-13
ASGCT 28th Annual Meeting 2025
New Orleans, U.S.A.
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
Scroll to Top